HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
Target trial emulation in Johannesburg shows dolutegravir associated with greater weight and blood pressure increases versus efavirenz
New HIV drug linked to higher weight and blood pressure in South Africa
This target trial emulation compared dolutegravir to efavirenz in 2930 treatment-naive individuals in Johannesburg, South Africa.
People starting a new HIV drug in South Africa gained more weight and saw higher blood pressure than those on an older treatment.
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …